New Guidelines on How to Treat HIV
Recommendations Shoot for 'Home Run' Against HIV Virus
Aug. 14, 2006 (Toronto) -- Potent drug therapies can suppress HIV to barely discernible levels in most people infected with the virus that causes AIDS -- even those who have failed other regimens, according to new HIV treatment guidelines.
In many instances, the recommendations of the International AIDS Society-USA Panel, released here at the International AIDS Conference, reflect only subtle changes from the group's 2004 guidelines.
But one major departure from years past is that "we can now hit a home run" even when one or more drug regimens stop working, says panel member Stefano Vella, MD, of the Istituto Superiore di Sanita in Rome.
For people started on new drugs after treatment failure, the goal is to drive the virus to undetectable levels, defined as fewer than 50 copies per milliliter of blood, says panel head Scott M. Hammer, MD, chief of the division of infectious diseases at Columbia University College of Physicians and Surgeons in New York City.
In the past, the panel recommended only that treatment decrease HIV levels by a factor of 10. The new regimen should include at least two and perhaps three new drugs, Hammer says. "Studies show that success is relative to the number of new agents."
22 Anti-HIV Drugs Now Available
The release of the recommendations of the 16-member panel coincide with the 25th anniversary of initial reports of what the world would come to know as the acquired immune deficiency syndrome.
Since then, AIDS has grown to pandemic proportions, resulting in 25 million deaths worldwide. Another 40 million people around the globe are living with HIV infection.
This year also marks the 10th anniversary of what doctors call highly active antiretroviral therapy, or HAART -- potent drug cocktails credited with transforming HIV from a death sentence into a chronic manageable disorder, like diabetesdiabetes.
"We now have 22 drugs in five different drug classes to choose from when caring for our patients," Hammer says.
Since the last guidelines were published, two new protease inhibitors -- Aptivus and Prezista -- were approved by the FDA. Their approval, combined with the continued refinement of older drug regimens, provided the rationale for creating the new guidelines, he tells WebMD.